SCHEMBL25414847

SCHEMBL25414847

Brc1cnn2cc(CCCN3CCCC3)ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.44
SIGMAR1 Q99720 4/20 0.43
HRH1 P35367 2/20 0.41
HRH3 Q9Y5N1 6/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
DRD2 P14416 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL3 Q96JM7 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
MCHR1 Q99705 1/20 0.37
CHRM2 P08172 1/20 0.37
ADRA2C P18825 1/20 0.37
SLC6A2 P23975 1/20 0.37
KCNH2 Q12809 1/20 0.37
CACNA1C Q13936 1/20 0.37
SCN5A Q14524 1/20 0.37
HRH4 Q9H3N8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17454474 0.80 SIGMAR1 (0.42) LTA4HSIGMAR1HRH1HRH3
SCHEMBL19675627 0.79 SIGMAR1 (0.41) LTA4HSIGMAR1HRH1HRH3SLC6A4
SCHEMBL25417457 0.79 CYP11B1 (0.40) LTA4HDRD2
SCHEMBL17452717 0.76 SIGMAR1 (0.39) LTA4HSIGMAR1HRH1HRH3L3MBTL1
SCHEMBL30374368 0.75 SIGMAR1 (0.43) LTA4HSIGMAR1HRH1HRH3SLC6A4
SCHEMBL19675383 0.75 SIGMAR1 (0.38) LTA4HSIGMAR1HRH1HRH3CYP3A4
SCHEMBL25416792 0.75 CA2 (0.33)
SCHEMBL19675379 0.74 HRH1 (0.39) LTA4HSIGMAR1HRH1HRH3
SCHEMBL25418034 0.73 LTA4H (0.51) LTA4HSIGMAR1HRH1HRH3SLC6A4
SCHEMBL18917604 0.72 LTA4H (0.75) LTA4HSIGMAR1HRH1HRH3SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2025-04-24 US disclosed
EP-4430047-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2024-09-18 EP disclosed
CN-118475580-A Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof 普罗根托斯治疗公司 2024-08-09 CN disclosed
WO-2023081923-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Frequency Therapeutics, Inc. (US) 2023-05-11 WO disclosed
WO-2023081923-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Frequency Therapeutics, Inc. (US) 2023-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PDGFRB, PDGFRA, PDGFA LTA4H 2495/4885SIGMAR1 4294/4885HRH1 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.